We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nondepleting Antibody Therapy Reverses Diabetes Symptoms in Mouse Model

By LabMedica International staff writers
Posted on 16 Jul 2012
A mouse diabetes model was treated by an immunotherapeutic approach based on novel nondepleting antibodies specific for the T-cell receptors CD4 and CD8.

Residual beta cells found at the time of the clinical onset of type I diabetes are sufficient to control hyperglycemia, if they can be rescued from ongoing autoimmune destruction. More...
To achieve this end, investigators at the University of North Carolina (Chapel Hill, NC, USA) developed an immunotherapeutic approach based on antibodies specific for the CD4 and CD8 receptors found on "autoreactive" T-cells. They then used these antibodies to treat members of a population of the mouse NOD diabetes model.

They reported in the June 29, 2012, online edition of the journal Diabetes that a short course of treatment with nondepleting antibodies specific for the CD4 and CD8 coreceptors rapidly reversed clinical disease in recent-onset diabetic NOD mice. Blood sugar levels returned to normal within 48 hours of treatment. Within five days, about 80% percent of the treated animals had entered diabetes remission with reversal of clinical symptoms.

Once established, remission was maintained indefinitely while immunity to foreign antigens was unimpaired. Induction of remission involved selective T-cell purging of the pancreas and draining pancreatic lymph nodes and upregulation of transforming growth factor (TGF)-beta1 by pancreas-resident antigen-presenting cells. Neutralization of TGF-beta1 blocked the induction of the remission process. In contrast, maintenance of remission was associated with tissue-specific immunoregulatory T cells.

"The protective effect is very rapid, and once established, is long-term," said senior author Dr. Roland Tisch, professor of microbiology and immunology at the University of North Carolina. "We followed the animals in excess of 400 days after the two antibody treatments, and the majority remained free of diabetes. And although the antibodies are cleared from within the animals in two to three weeks after treatment, the protective effect persists."

"We have demonstrated that the use of nondepleting antibodies is very robust," said Dr. Tisch. "We are now generating and plan to test antibodies that are specific for the human version of the CD4 and CD8 molecules."

Related Links:

University of North Carolina School



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.